Metastatic melanoma in the older patient: Immunologic insights and treatment outcomes

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 2, 2011, Pages 185-193

  Hegde, Upendra P ^a   Chakraborty, Nitya ^a   Mukherji, Bijay ^a   Grant Kels, Jane M ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

adaptive immune system; aging; cytokines; cytotoxic T lymphocyte; immune balance; metastatic melanoma; regulatory T lymphocyte

Indexed keywords

DENDRITIC CELL VACCINE; IPILIMUMAB; MELANOMA VACCINE; T LYMPHOCYTE RECEPTOR;

ADAPTIVE IMMUNITY; AGING; ANTIGEN PRESENTING CELL; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EARLY DIAGNOSIS; HOMEOSTASIS; HUMAN; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LIFESTYLE; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MELANOMA; METASTASIS; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; RISK BENEFIT ANALYSIS; SENESCENCE; SEX DIFFERENCE; SOCIAL STATUS; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH;

AGE FACTORS; AGED; AGING; HUMANS; IMMUNE SYSTEM; MELANOMA; PROGNOSIS;

EID: 79953862196     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.14     Document Type: Review

References (41)

1. Geller AC, Miller DR, Annas GD et al. Melanoma incidence and mortality among US whites, 1969-1999. JAMA 288, 1719-1720 (2002).
2. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classifcation. J. Clin. Oncol. 36, 6199-6206 (2009).
3. American Cancer Society. Cancer Facts and Figures 2010. American Cancer Society Atlanta, GA, USA (2010).
4. Marks R. An overview of skin cancers: incidence and causation. Cancer 75, 607-612 (1995).
5. Roush GC, McKay L, Holford TR. A reversal in the long-term increase in death attributable to malignant melanoma. Cancer 69, 1714-1720 (1992).
6. Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC. Economic burden of melanoma in the elderly population. Arch. Dermatol. 146, 249-256 (2010).
7. Cohen HJ, Cox E, Manton K, Woodbury M. Malignant melanoma in the elderly. J. Clin. Oncol. 5, 100-106 (1987). (Pubitemid 17007863)
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
9. Chang CK, Jacobs IA, Vizgirda VM, Salti GI. Melanoma in the elderly patient. Arch. Surg. 138, 1135-1138 (2003). (Pubitemid 37238602)
10. McMasters KM, Noyes RD, Reintgen DS et al. Sunbelt Melanoma Trial. J. Surg. Oncol. 86(4), 212-223 (2004).
11. Chao C, Martin RC 2nd, Ross MI et al. Correlation between prognostic factors and increasing age in melanoma. Ann. Surg Oncol. 11, 259-264 (2004). (Pubitemid 40486765)
12. Ortiz CA, Goodwin JS, Freeman JL. The effect of socioeconomic factors on incidence, stage at diagnosis and survival of cutaneous melanoma. Med. Sci. Monit. 11, RA163-RA172 (2005). (Pubitemid 40790954)
13. Reyes Ortiz CA, Freeman JL, Kuo YF, Goodwin JS. The infuence of marital status on stage at diagnosis and survival of older persons with melanoma. J. Gerontol. A Biol. Sci. Med. Sci. 62, 892-898 (2007). (Pubitemid 350131675)
14. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors ana lysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19, 3622-3634 (2001). (Pubitemid 32786275)
15. Lasithiotakis KG, Petrakis LE, Garbe C Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Mel. Res. 20, 163-170 (2010).
16. Ershler WB, Stewart JA, Hacker MP, Moore AL, Tindle BH. B16 murine melanoma and aging: slower growth and longer survival in older mice. J. Natl Cancer Inst. 72, 161-164 (1984). (Pubitemid 14159243)
17. Hirayama R, Sato K, Hirokawa K et al. Different metastatic modes of malignant melanoma implanted in the ear of young and old mice. Cancer Immunol. Immunother. 18, 209-214 (1984). (Pubitemid 15179774)
18. Kaptzan T, Skutelsky E, Itzhaki O et al. Effcacy of anti-angiogenic treatment of tumors in old versus young mice. Mech. Ageing Dev. 127, 398-409 (2006). (Pubitemid 43290544)
19. Brand CU, Ellwanger U, Stroebel W et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 79, 2345-2353 (1997). (Pubitemid 27251017)
20. Eton O, Legha SS, Moon TE et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J. Clin. Oncol. 16, 1103-1111 (1998). (Pubitemid 28108747)
21. Boon T, Coulie PG, Van den Eynde BJ et al. Human T cell responses against melanoma. Ann. Rev. Immunol. 24, 1-34 (2006).
22. Mukherji B, Chakraborty NG, Yamasaki S et al. Induction of antigen-specifc cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl Acad. Sci. USA 92, 8078-8082 (1995).
23. Sakaguchi S, Takahashi T, Nishizuka Y. Study on cellular events in post-thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis. J. Exp. Med. 156, 1577-1586 (1982). (Pubitemid 13167406)
24. + T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines. J. Immunol. 162, 5576-5583 (1999). (Pubitemid 29307171)
25. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev. 8, 299-308 (2008). (Pubitemid 351430867)
26. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl. J. Med. 363, 711-723 (2010).
27. Pawelec G, Solana R, Remarque E, Mariani E. Impact of aging on innate immunity. J. Leukoc. Biol. 64, 703-712 (1998). (Pubitemid 28555382)
28. Aspinall R. Age-related changes in the function of T cells. Micro Res. Tech. 62, 508-513 (2003). (Pubitemid 37467328)
29. - dendritic cell function. J. Gerontol. Biol. Sci. 61A, 1039-1047 (2006). (Pubitemid 44727211)
30. Hegde UP, Chakraborty N, Kerr P, Grant-Kels JM. Melanoma in the elderly patient. Clin. Dermatol. 27, 537-544 (2009).
31. Christenson B, Pauksen K, Sylvan PE. Effect of infuenza and pneumococcal vaccines in elderly persons in years of low infuenza activity Virol. J. 5, 1-9 (2008).
32. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin. Infect. Dis. 42, 1093-1101 (2006).
33. Atzpodien J, Wandert T, Reitz M. Age does not impair the effcacy of immunotherapy in patients with metastatic renal cell carcinoma. Crit. Rev. Oncol. Hematol. 55, 193-199 (2005). (Pubitemid 41219691)
34. Quan W Jr, Ramirez M, Taylor C et al. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over. Cancer Biother. Radiopharm. 20, 11-15 (2005). (Pubitemid 40478516)
35. Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival ana lysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 106, 1353-1357 (2006). (Pubitemid 43363914)
36. Ribas A, Camacho LH, Lopez-Berestein G. et al. Anti-tumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 23, 8968-8977 (2005). (Pubitemid 46217464)
37. Marshall J, Forester TH, Purdie DM et al. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. Immunol. Cell Biol. 84, 295-302 (2006).
38. Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE. Aging, immunity and cancer. Curr. Opin. Immunol. 16, 151-156 (2004). (Pubitemid 38328716)
39. + Tregs cells reveals an age-dependent loss of suppressive activity J. Neurosci. Res. 74, 296-308 (2003). (Pubitemid 37193716)
40. high regulatory T cells increases with age. Clin. Exp. Immunol. 140, 1365-2249 (2005).
41. Hegde UP, Chhabra A, Chakraborty NG. Lack of Tregs cell function and melanoma tumor antigen-specifc responses in some elderly patients. Presented at: 99th Annual Meeting of American Association of Cancer Research. San Diego, CA, USA, 12-16 April 2008.